Wow!
Longeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare pediatric disease designation
Longeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare p
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
5
举报
登录后可参与评论
暂无评论